SRNE - Sorrento gets FDA greenlight for early-stage CD38 DAR-T multiple myeloma study

Sorrento Therapeutics (NASDAQ:SRNE) announces that the U.S. FDA has authorized the company's IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed or refractory multiple myeloma. The company highlighted that CD38 DAR-T cell therapy candidate showed strong cytotoxic activity in preclinical studies. DAR-T technology is designed to potentially provide a significant advancement to the timeliness and potency of treatments for patient populations who have already undergone multiple rounds of chemotherapy and are suffering from persistent disease. "We foresee the first 'Off-the-Shelf' DAR-T trial will open the door to numerous other DAR-T cell therapies for other indications to follow," CEO Henry Ji said. Shares up more than 3% premarket.

For further details see:

Sorrento gets FDA greenlight for early-stage CD38 DAR-T multiple myeloma study